Health technology assessment in osteoporosis

Calcified Tissue International

Volumn 93, Issue 1, 2013, Pages 1-14

  Hiligsmann, Mickael ^a,b   Kanis, John A ^c   Compston, Juliet ^d   Cooper, Cyrus ^e   Flamion, Bruno ^f   Bergmann, Pierre ^g   Body, Jean Jacques ^g   Boonen, Steven ^h   Bruyere, Olivier ^b   Devogelaer, Jean Pierre ⁱ   Goemaere, Stefan ^j   Kaufman, Jean Marc ^j   Rozenberg, Serge ^k   Reginster, Jean Yves ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF NAMUR   (Belgium)

^g BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Burden of disease; Cost effectiveness; Economic evaluation; Health technology assessment; Osteoporosis

Indexed keywords

BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; ODANACATIB; STRONTIUM RANELATE; ZOLEDRONIC ACID;

CLINICAL ASSESSMENT TOOL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FOREARM FRACTURE; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HIP FRACTURE; HUMAN; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SPINE FRACTURE; TOTAL QUALITY MANAGEMENT;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84875048613     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9724-8     Document Type: Review

References (136)

1. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633-1650
2. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-112
3. Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991-994
4. Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669-674
5. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239-2256
6. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237-1244
7. Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99-105
8. Ström O, Borgström F, Kanis J et al (2011) Osteoporosis: burden, health care provision and opportunities in the European Union. Arch Osteoporos 6:59-155
9. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57
10. International Network of Agencies of Health Technology Assessment (2012) INAHTA Health Technology Assessment Glossary. http://www.inahta.org/HTA/ Glossary/#-Health-Technology-Assessment. Cited 1 April 2012
11. Jonsson E, Banta D (1999) Management of health technologies: an international view. BMJ 319:1293-1295
12. Banta D, Jonsson E (2009) History of HTA: introduction. Int J Technol Assess Health Care 25(Suppl 1):1-6
13. Martelli F, La Torre G, Di Ghionno E et al (2007) Health technology assessment agencies: an international overview of organizational aspects. Int J Technol Assess Health Care 23:414-424
14. Oliver A, Mossialos E, Robinson R (2004) Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care 20:1-10
15. Banta D, Oortwijn W (2000) Health technology assessment and health care in the European Union. Int J Technol Assess Health Care 16:626-635
16. Goodman CS (2004) HTA 101: introduction to health technology assessment. http://www.nlm.nih.gov/nichsr/hta101/hta101.pdf. Cited 1 April 2012
17. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-1010
18. van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517-522
19. Dhanwal DK, Cooper C, Dennison EM (2010) Geographic variation in osteoporotic hip fracture incidence: the growing importance of Asian influences in coming decades. J Osteoporos 2010:757102
20. Johnell O, Borgstrom F, Jonsson B, Kanis J (2007) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18:333-337
21. Elffors I, Allander E, Kanis JA et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS study. Osteoporos Int 4:253-263
22. Roy DK, Pye SR, Lunt M et al (2002) Falls explain between-center differences in the incidence of limb fracture across Europe. Bone 31:712-717
23. Langley J, Samaranayaka A, Davie G, Campbell AJ (2011) Age, cohort and period effects on hip fracture incidence: analysis and predictions from New Zealand data 1974-2007. Osteoporos Int 22:105-111
24. Martyn CN, Cooper C (1999) Prediction of burden of hip fracture. Lancet 353:769-770
25. Javaid MK, Crozier SR, Harvey NC et al (2006) Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet 367:36-43
26. Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-289
27. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573-1579
28. Cooper C, Cole ZA, Holroyd CR et al (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277-1288
29. Melton LJ 3rd, Kearns AE, Atkinson EJ et al (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687-694
30. Hiligsmann M, Bruyere O, Roberfroid D et al (2012) Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007). Arthritis Care Res (Hoboken) 64:744-750
31. Reginster JY, Gillet P, Gosset C (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 79:942-946
32. Abrahamsen B, Vestergaard P (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 21:373-380
33. Melton LJ 3rd, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895-897
34. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276-1287
35. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
36. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170-177
37. Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48:380-388
38. Silverman SL, Christiansen C, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923-1934
39. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
40. Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661
41. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822
42. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
43. Cooper C, Reginster JY, Cortet B et al (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475-491
44. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41:58-69
45. Devogelaer JP, Goemaere S, Boonen S et al (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8-19
46. Body JJ, Bergmann P, Boonen S et al (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 21:1657-1680
47. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
48. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046
49. Ensrud KE, Lui LY, Taylor BC et al (2009) A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 169:2087-2094
50. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229
51. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109-1117
52. Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423-431
53. Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395-2411
54. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839-847
55. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809-816
56. Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 27:645-653
57. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821-828
58. Kayan K, Johansson H, Oden A et al (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055-2061
59. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
60. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
61. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652
62. Rabenda V, Reginster JY (2010) Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res 10:677-689
63. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571-581
64. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604-612
65. Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127-2134
66. Hiligsmann M, Salas M, Hughes DA et al (2011) Most effective adherence-enhancing interventions for osteoporosis medications. ISPOR 16th Annual International Meeting Abstracts, Baltimore, MD, 21-25 May 2011. Value Health 14:A130
67. Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317-326
68. Montori VM, Shah ND, Pencille LJ et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549-556
69. Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81:155-160
70. Drummond M, Sculpher M, O'Brien B, Stoddart G, Torrance G (2007) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York
71. Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972-975
72. Drummond M, Jonsson B, Rutten F (1997) The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40:199-215
73. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441-449
74. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565-2573
75. Palmer S, Byford S, Raftery J (1999) Economics notes: types of economic evaluation. BMJ 318:1349
76. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18:9-23
77. Briggs A, Claxton K, Sculpher M (2007) Decision modelling for health economic evaluation, 2nd edn. Oxford University Press, New York
78. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300-1303
79. World Health Organization (2011) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Cited 10 April 2012
80. ® in Switzerland. Osteoporos Int 23:2579-2589
81. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459-1471
82. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M (2008) Threshold values for cost-effectiveness in health care. Health technology assessment (HTA). KCE Reports 100B (D/2008/10.273/95). Belgian Health Care Knowledge Centre, Brussels
83. George B, Harris A, Mitchell A (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19:1103-1109
84. Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13:437-452
85. National institute for Health and Clinical Excellence (2012) Appraising life-extending, end of life treatments. http://www.nice.org.uk/media/88A/F2/ SupplementaryAdviceTACEoL.pdf. Cited 10 April 2012
86. Petrou S, Gray A (2011) Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 342:d1548
87. Petrou S, Gray A (2011) Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 342:d1766
88. OBrien B (1996) Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 34:DS99-DS108
89. Sculpher MJ, Claxton K, Drummond M, McCabe C (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15:677-687
90. Brennan A, Akehurst R (2000) Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 17:445-459
91. Buxton MJ, Drummond MF, Van Hout BA et al (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217-227
92. Sheldon TA (1996) Problems of using modelling in the economic evaluation of health care. Health Econ 5:1-11
93. Kassirer JP, Angell M (1994) The journal's policy on cost-effectiveness analyses. N Engl J Med 331:669-670
94. National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/nicemedia/ live/11704/51970/51970.pdf
95. Kanis J, McCloskey E, Jonsson B, Cooper A, Ström O, Borgström F (2012) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19-48
96. Fleurence RL, Spackman DE, Hollenbeak C (2010) Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 28:295-306
97. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment (2000) Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Pharmacoeconomics 17:443-444
98. Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895-911
99. Fenwick E, O'Brien BJ, Briggs A (2004) Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 13:405-415
100. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338
101. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687-696
102. Muller D, Pulm J, Gandjour A (2012) Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health 15:284-298
103. Zethraeus N, Ben Sedrine W, Caulin F et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841-857
104. Hiligsmann M, Reginster JY (2012) Health economics in osteoporosis. Temas de osteoporosis y otras enfermedades oseas. 337-358
105. Fleurence RL, Iglesias CP, Johnson JM (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 25:913-933
106. Fleurence RL, Iglesias CP, Torgerson DJ (2006) Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 17:29-40
107. Schousboe JT (2008) Cost effectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen and who do we treat? Appl Health Econ Health Policy 6:1-18
108. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157-165
109. Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34-40
110. Borgstrom F, Kanis JA (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885-900
111. Jonsson B, Strom O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967-982
112. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440-446
113. Akehurst R, Brereton N, Ariely R et al (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ 14:53-64
114. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
115. ® with and without bone mineral density. Calcif Tissue Int 90:1-13
116. Strom O, Borgstrom F, Kleman M et al (2010) FRAX and its applications in health economics - cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430-437
117. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int 19:1395-1408
118. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
119. ® model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453-461
120. Danese MD, Badamgarav E, Bauer DC (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24:1819-1826
121. Cotte FE, Cortet B, Lafuma A et al (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75:201-208
122. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-210
123. Rietbrock S, Olson M, van Staa TP (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102:35-42
124. Patrick AR, Schousboe JT, Losina E, Solomon DH (2011) The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab 96:2762-2770
125. Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
126. Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12:159-166
127. Hutton J, Trueman P, Facey K (2008) Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care 24:511-517
128. Drummond M, Barbieri M, Cook J et al (2009) Transferability of economic evaluations across jurisdictions: iSPOR Good Research Practices Task Force report. Value Health 12:409-418
129. Drummond MF, Schwartz JS, Jonsson B et al (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24(244-258):362-368
130. Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24:1043-1053
131. Hoaglin DC, Hawkins N, Jansen JP et al (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14:429-437
132. Darba J, Restovic G, Kaskens L et al (2011) Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int 22:1947-1954
133. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW (2008) Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 19:1029-1037
134. Lancsar E, Louviere J (2008) Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 26:661-677
135. Ryan M (2004) Discrete choice experiments in health care. BMJ 328:360-361
136. Humphreys K, Piot P (2012) Scientific evidence alone is not sufficient basis for health policy. BMJ 344:e1316